DEA
WST icon

DoubleLine ETF Adviser’s West Pharmaceutical WST Stock Holding History

DoubleLine ETF Adviser’s Portfolio WST Stock Details WST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$285K Sell
793
-93
-10% -$28.4K 0.12% 149
2026
Q1 		$222K Buy
+886
New +$220K 0.08% 164

Other funds holding WST

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
GIM
Generation Investment Management London, United Kingdom $10.3B AUM 4.84% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

DoubleLine ETF Adviser's WST Position: Q2 2026 in Review

DoubleLine ETF Adviser reduced its West Pharmaceutical (WST) stake by 10% in Q2 2026, selling an estimated $28.4K and leaving 793 shares worth $285K. The position accounts for 0.12% of the portfolio, ranked #149.

DoubleLine ETF Adviser first reported a position in WST in Q1 2026 and has held it in 2 quarters since. 831 funds tracked by Wall St. Rank hold WST as of Q2 2026.

  • DoubleLine ETF Adviser held 793 shares of West Pharmaceutical worth $285K as of Q2 2026.
  • DoubleLine ETF Adviser sold 93 West Pharmaceutical shares in Q2 2026, an estimated $28.4K.
  • West Pharmaceutical made up 0.12% of DoubleLine ETF Adviser's portfolio in Q2 2026, its #149 holding.
  • DoubleLine ETF Adviser first reported a position in West Pharmaceutical in Q1 2026 and has held it in 2 quarters since.
  • 831 funds tracked by Wall St. Rank held West Pharmaceutical as of Q2 2026.

Based on DoubleLine ETF Adviser's 13F filing for Q2 2026, filed 14 Aug 2026.